Diagnostics company Oxford Immunotec, backed by Dow Chemical Company and Kaiser Permanente Ventures, raises $62.8m in IPO.
US-based Oxford Immunotec, a medical diagnostics company, has closed its initial public offering (IPO) with 5,360,000 shares priced at $13 to $15 per share under the ticker symbol “OXFD.” The underwriters had the option to purchase up to 804,000 additional ordinary shares. The company had expected to raise around $63.8m which would have valued the company at $229.1m, but instead raised $62.8m.
J.P. Morgan and Piper Jaffray & Co served as lead underwriters.
Oxford has so far raised $107m in funding. Last year…
